Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909845 | PMC |
| http://dx.doi.org/10.1161/CIRCGEN.123.004526 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Effects and mechanisms of total flavones of Abelmoschus manihot combined with empagliflozin in attenuating diabetic tubulopathy through multiple targets based on mitochondrial homeostasis and ZBP1-mediated PANoptosis].
Zhongguo Zhong Yao Za Zhi
July 2025
Jiangsu Suzhong Pharmaceutical Research Institute Nanjing 210031,China.
This study aimed to explore the mechanisms and molecular targets of total flavones of Abelmoschus manihot(TFA) plus empagliflozin(EM) in attenuating diabetic tubulopathy(DT) by targeting mitochondrial homeostasis and pyroptosis-apoptosis-necroptosis(PANoptosis). In the in vivo study, the authors established the DT rat models through a combination of uninephrectomy, administration of streptozotocin via intraperitoneal injections, and exposure to a high-fat diet. Following modeling successfully, the DT rat models received either TFA, EM, TFA+EM, or saline(as a vehicle) by gavage for eight weeks, respectively.
View Article and Find Full Text PDFEmpagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5/6 nephrectomy.
Biomed Pharmacother
August 2025
Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Germany; Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, China; IMD Institut für Medizinische Diagnostik Berlin-Potsdam GbR, Berlin, Germany.
Left ventricular hypertrophy (LVH) is a common cardiac complication in patients with cardiorenal syndrome. Empagliflozin has demonstrated cardio-renal protective effects in clinical studies, potentially linked to reductions in left ventricular mass (LVM). Using a 5/6 nephrectomy rat model to induce cardiorenal syndrome, we administered two doses of Empagliflozin (3 mg/kg/day and 15 mg/kg/day) via gavage for 95 days, with Telmisartan as a positive control.
View Article and Find Full Text PDFEmpagliflozin alleviates doxorubicin-induced myocardial injury by inhibiting RIP3-dependent TLR4/MyD88/NF-κB signaling pathway.
Biochem Pharmacol
August 2025
Department of Cardiology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China. Electronic address:
Doxorubicin (DOX), a widely used chemotherapeutic agent, is associated with dose-dependent cardiotoxicity that limits its clinical application. Emerging evidence implicates that receptor-interacting protein kinase 3 (RIP3) and the Toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/nuclear factor kappa-B (NF-κB) signaling pathway play pivotal roles in DOX-induced cardiac inflammation and cell death. Empagliflozin, an sodium-glucose co-transporter 2 (SGLT2) inhibitor, has shown potential cardioprotective effects independent of its glucose-lowering actions.
View Article and Find Full Text PDFImmunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013-2025).
Eur J Med Chem
August 2025
Department of Endocrinology and Metabolism, Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. Electronic address:
Diabetes mellitus (DM) is both a metabolic and chronic inflammatory disease, wherein immune dysregulation contributes to multisystem complications. Beyond glycemic control, anti-diabetic agents-Metformin (Met), sodium-glucose cotransporter 2 inhibitors (SGLT-2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)-exert immunomodulatory effects through cytokine and chemokine modulation. This review summarizes mechanistic and experimental findings (2013-2025), showing that Met suppresses pro-inflammatory cytokines (e.
View Article and Find Full Text PDFEmpagliflozin attenuates liver steatosis and improves cardiac complications in choline-deficient high-fat diet-induced MAFLD rats.
Eur J Pharmacol
August 2025
Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Guwahati, 781101, Assam, India. Electronic address:
Growing evidence suggests a strong relation between metabolic dysfunction-associated fatty liver disease (MAFLD) and cardiovascular disease (CVD). Limited approaches are available to reduce CVD risk in MAFLD. Recent evidence suggests that Sodium-glucose transporter 2 (SGLT2) inhibitors represent a promising class of drugs for managing MAFLD.
View Article and Find Full Text PDF